NEUROPHARMAGEN Trademark
Trademark Overview
On Monday, July 29, 2024, a trademark application was filed for NEUROPHARMAGEN with the United States Patent and Trademark Office. The USPTO has given the NEUROPHARMAGEN trademark a serial number of 98671767. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, May 9, 2025. This trademark is owned by PRECISION MOLECULAR SOLUTIONS LLC. The NEUROPHARMAGEN trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical services; Medical diagnostic services; Medical analysis services for the treatment of persons; Genetic testing for medical purposes; Performing diagnosis of diseases; Medical analysis for the diagnosis and treatment of persons; Remote monitoring of medical data for medical diagnosis and treatment; Genetic analysis in order to increase the efficiency of treatments for patients for medical purposes; Services for the preparation of medical reports, namely, providing information to medical professionals in the form of reports in the field of pharmacogenetics; Information, advice and consultancy regarding all aforementioned services
Software as a service (SAAS) featuring software for information, advice and consultancy in the field of pharmacogenetics; Platform as a Service (PAAS) featuring computer platforms for information, advice and consultancy in the field of pharmacogenetics; Science and technology services, namely analysis in the field of pharmacogenetics; Genetic research; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Medical and pharmacological research services; Design and development of medical technology; Design and development of computer software for use with medical technology; Pharmaceutical products development; Research laboratory analysis in the field of genetics; Scientific research in the nature of conducting clinical trials for others; Structural and functional analysis of genomes; Research in the field of pharmacogenetics; Information, advice and consultancy regarding all aforementioned services
General Information
| Serial Number | 98671767 |
| Word Mark | NEUROPHARMAGEN |
| Filing Date | Monday, July 29, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Friday, May 9, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of the word "NEUROPHARMAGEN" in green lettering. |
| Indication of Colors claimed | The color green is claimed as a feature of the mark. |
| Goods and Services | Medical services; Medical diagnostic services; Medical analysis services for the treatment of persons; Genetic testing for medical purposes; Performing diagnosis of diseases; Medical analysis for the diagnosis and treatment of persons; Remote monitoring of medical data for medical diagnosis and treatment; Genetic analysis in order to increase the efficiency of treatments for patients for medical purposes; Services for the preparation of medical reports, namely, providing information to medical professionals in the form of reports in the field of pharmacogenetics; Information, advice and consultancy regarding all aforementioned services |
| Goods and Services | Software as a service (SAAS) featuring software for information, advice and consultancy in the field of pharmacogenetics; Platform as a Service (PAAS) featuring computer platforms for information, advice and consultancy in the field of pharmacogenetics; Science and technology services, namely analysis in the field of pharmacogenetics; Genetic research; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Medical and pharmacological research services; Design and development of medical technology; Design and development of computer software for use with medical technology; Pharmaceutical products development; Research laboratory analysis in the field of genetics; Scientific research in the nature of conducting clinical trials for others; Structural and functional analysis of genomes; Research in the field of pharmacogenetics; Information, advice and consultancy regarding all aforementioned services |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, July 29, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, July 29, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | PRECISION MOLECULAR SOLUTIONS LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Barcelona 08907
ES |
Trademark Events
| Event Date | Event Description |
| Monday, July 29, 2024 | NEW APPLICATION ENTERED |
| Wednesday, November 27, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, November 27, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, November 27, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, November 27, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, November 27, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, February 13, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, February 19, 2025 | NON-FINAL ACTION E-MAILED |
| Friday, February 14, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, February 19, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, February 19, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, May 9, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, May 9, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, May 9, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
